Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation

Hisashi Gondo, Toshio Minematsu, Mine Harada, Koichi Akashi, Shin Hayashi, Shuichi Taniguchi, Kazuo Yamasaki, Tsunefumi Shibuya, Yasushi Takamatsu, Takanori Teshima, Tetsuya Eto, Koji Nagafuji, Shinichi Mizuno, Kenji Hosoda, Ryoichi Mori, Yoichi Minamishima, Yoshiyuki Niho

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

A technique for the rapid detection of cytomegalovirus (CMV) antigen‐positive blood leucocytes (CMV antigenaemia) was evaluated in 15 marrow transplant patients as a means of diagnosis and for monitoring CMV‐associated disease. CMV antigenaemia was determined by direct immunoperoxidase staining of leucocytes with a peroxidase‐labelled monoclonal antibody, HRP‐C7, which binds an immediate‐early antigen of human CMV. CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV‐associated diseases developed in 3/15 patients (20%). All patients with CMV‐associated disease had a relatively large number of CMV antigen‐positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen‐positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV‐associated disease did not develop in these patients during the period of monitoring. CMV antigen‐positive leucocytes were detected more frequently in patients who developed acute graft‐versus‐host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV‐associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen‐positive blood leucocytes is useful for the diagnosis and monitoring of CMV‐associated disease following bone marrow transplantation.

Original languageEnglish
Pages (from-to)130-137
Number of pages8
JournalBritish Journal of Haematology
Volume86
Issue number1
DOIs
Publication statusPublished - Jan 1 1994

Fingerprint

Cytomegalovirus
Bone Marrow Transplantation
Leukocytes
Bone Marrow
Transplants
Antigens
Ganciclovir
Cystitis
Acute Disease
Signs and Symptoms
Transplantation
Monoclonal Antibodies
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation. / Gondo, Hisashi; Minematsu, Toshio; Harada, Mine; Akashi, Koichi; Hayashi, Shin; Taniguchi, Shuichi; Yamasaki, Kazuo; Shibuya, Tsunefumi; Takamatsu, Yasushi; Teshima, Takanori; Eto, Tetsuya; Nagafuji, Koji; Mizuno, Shinichi; Hosoda, Kenji; Mori, Ryoichi; Minamishima, Yoichi; Niho, Yoshiyuki.

In: British Journal of Haematology, Vol. 86, No. 1, 01.01.1994, p. 130-137.

Research output: Contribution to journalArticle

Gondo, H, Minematsu, T, Harada, M, Akashi, K, Hayashi, S, Taniguchi, S, Yamasaki, K, Shibuya, T, Takamatsu, Y, Teshima, T, Eto, T, Nagafuji, K, Mizuno, S, Hosoda, K, Mori, R, Minamishima, Y & Niho, Y 1994, 'Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation', British Journal of Haematology, vol. 86, no. 1, pp. 130-137. https://doi.org/10.1111/j.1365-2141.1994.tb03263.x
Gondo, Hisashi ; Minematsu, Toshio ; Harada, Mine ; Akashi, Koichi ; Hayashi, Shin ; Taniguchi, Shuichi ; Yamasaki, Kazuo ; Shibuya, Tsunefumi ; Takamatsu, Yasushi ; Teshima, Takanori ; Eto, Tetsuya ; Nagafuji, Koji ; Mizuno, Shinichi ; Hosoda, Kenji ; Mori, Ryoichi ; Minamishima, Yoichi ; Niho, Yoshiyuki. / Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation. In: British Journal of Haematology. 1994 ; Vol. 86, No. 1. pp. 130-137.
@article{f59352fb15814d0dad39d51e8f403839,
title = "Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation",
abstract = "A technique for the rapid detection of cytomegalovirus (CMV) antigen‐positive blood leucocytes (CMV antigenaemia) was evaluated in 15 marrow transplant patients as a means of diagnosis and for monitoring CMV‐associated disease. CMV antigenaemia was determined by direct immunoperoxidase staining of leucocytes with a peroxidase‐labelled monoclonal antibody, HRP‐C7, which binds an immediate‐early antigen of human CMV. CMV antigenaemia occurred in 7/15 marrow transplant patients (47{\%}) and was initially detected between 4 and 6 weeks after transplantation. CMV‐associated diseases developed in 3/15 patients (20{\%}). All patients with CMV‐associated disease had a relatively large number of CMV antigen‐positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen‐positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV‐associated disease did not develop in these patients during the period of monitoring. CMV antigen‐positive leucocytes were detected more frequently in patients who developed acute graft‐versus‐host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV‐associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen‐positive blood leucocytes is useful for the diagnosis and monitoring of CMV‐associated disease following bone marrow transplantation.",
author = "Hisashi Gondo and Toshio Minematsu and Mine Harada and Koichi Akashi and Shin Hayashi and Shuichi Taniguchi and Kazuo Yamasaki and Tsunefumi Shibuya and Yasushi Takamatsu and Takanori Teshima and Tetsuya Eto and Koji Nagafuji and Shinichi Mizuno and Kenji Hosoda and Ryoichi Mori and Yoichi Minamishima and Yoshiyuki Niho",
year = "1994",
month = "1",
day = "1",
doi = "10.1111/j.1365-2141.1994.tb03263.x",
language = "English",
volume = "86",
pages = "130--137",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV‐associated disease after bone marrow transplantation

AU - Gondo, Hisashi

AU - Minematsu, Toshio

AU - Harada, Mine

AU - Akashi, Koichi

AU - Hayashi, Shin

AU - Taniguchi, Shuichi

AU - Yamasaki, Kazuo

AU - Shibuya, Tsunefumi

AU - Takamatsu, Yasushi

AU - Teshima, Takanori

AU - Eto, Tetsuya

AU - Nagafuji, Koji

AU - Mizuno, Shinichi

AU - Hosoda, Kenji

AU - Mori, Ryoichi

AU - Minamishima, Yoichi

AU - Niho, Yoshiyuki

PY - 1994/1/1

Y1 - 1994/1/1

N2 - A technique for the rapid detection of cytomegalovirus (CMV) antigen‐positive blood leucocytes (CMV antigenaemia) was evaluated in 15 marrow transplant patients as a means of diagnosis and for monitoring CMV‐associated disease. CMV antigenaemia was determined by direct immunoperoxidase staining of leucocytes with a peroxidase‐labelled monoclonal antibody, HRP‐C7, which binds an immediate‐early antigen of human CMV. CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV‐associated diseases developed in 3/15 patients (20%). All patients with CMV‐associated disease had a relatively large number of CMV antigen‐positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen‐positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV‐associated disease did not develop in these patients during the period of monitoring. CMV antigen‐positive leucocytes were detected more frequently in patients who developed acute graft‐versus‐host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV‐associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen‐positive blood leucocytes is useful for the diagnosis and monitoring of CMV‐associated disease following bone marrow transplantation.

AB - A technique for the rapid detection of cytomegalovirus (CMV) antigen‐positive blood leucocytes (CMV antigenaemia) was evaluated in 15 marrow transplant patients as a means of diagnosis and for monitoring CMV‐associated disease. CMV antigenaemia was determined by direct immunoperoxidase staining of leucocytes with a peroxidase‐labelled monoclonal antibody, HRP‐C7, which binds an immediate‐early antigen of human CMV. CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV‐associated diseases developed in 3/15 patients (20%). All patients with CMV‐associated disease had a relatively large number of CMV antigen‐positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen‐positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV‐associated disease did not develop in these patients during the period of monitoring. CMV antigen‐positive leucocytes were detected more frequently in patients who developed acute graft‐versus‐host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV‐associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen‐positive blood leucocytes is useful for the diagnosis and monitoring of CMV‐associated disease following bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0028303991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028303991&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.1994.tb03263.x

DO - 10.1111/j.1365-2141.1994.tb03263.x

M3 - Article

C2 - 8011521

AN - SCOPUS:0028303991

VL - 86

SP - 130

EP - 137

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -